Clinical Trials Logo

Filter by:
NCT ID: NCT03249285 Recruiting - Hypertension Clinical Trials

Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)

PGX-HT
Start date: March 2016
Phase: Phase 3
Study type: Interventional

This is a pharmacogenomic prospective , four-arms, parallel groups, active comparator controlled study in essential hypertensive patients never treated before. Each patient will be genotyped for SNPs (single nucleotide polymorphism) in preliminary genetic profiles and will be treated according to their genetic profile with Peri (Perindopril) 4 mg or HCTZ ( hydrochlorothiazide) 12.5 mg.

NCT ID: NCT03247868 Recruiting - Clinical trials for Cervical Dystonia,Primary

A Multimodal Approach to Cervical Dystonia Treatment With Association of Botulinum Toxin and Motor Learning Techniques

SPRInt
Start date: March 16, 2016
Phase: N/A
Study type: Interventional

the aim of this study protocol is to describe, using a longitudinal study, a multimodal approach of treatment of cervical dystonia with botulinum toxin (BoNTA) and a new rehabilitation protocol named SPRInt (Sensory-motor perceptive rehabilitation integrated) approach based on motor learning techniques and spatial rehabilitation.

NCT ID: NCT03244735 Completed - Clinical trials for Chronic Cluster Headache

Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series

CCHD
Start date: January 2017
Phase: N/A
Study type: Interventional

Atkins diet is a nutritional regimen characterized by ad libitum protein and fat intake, but carbohydrate restriction. It is followed by millions of people around the word as a life-style, but in the last years was proposed as a treatment for the epilepsy, by its capacity to induce the state of ketosis. Since Authors observed that ketosis could be also useful in migraine, and migraine shares some pathophysiological features with cluster headache, The aim of the study is to test the efficacy of Atkins diet in Cluster Headache by an open label one harm observational study.

NCT ID: NCT03244709 Recruiting - Clinical trials for Giant Cell Arteritis

Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.

Start date: January 1, 2015
Phase: Phase 4
Study type: Interventional

Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA). Based on this rationale, several recent studies demonstrated the efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, for the treatment of patients with refractory GCA. Confirming previous reports,in a recent retrospective study the investigators successfully treated 10 patient with refractory GCA with TCZ. All patients achieved a complete disease remission evaluated by clinical, laboratory, and positron emission tomography (PET). In a considerable number of GCA patients treated with corticosteroids (CS) the therapy may be interrupted with no disease flares. No data are available on the management of patients achieving the remission with TCZ.

NCT ID: NCT03242109 Completed - Diabetes Clinical Trials

The Moli-sani Study

Start date: March 1, 2005
Phase: N/A
Study type: Observational

Cardiovascular disease and malignancies account for more than 70% of all causes of mortality and morbidity in Italy. There is a subtle balance between genetic determinants and lifestyle, that often defines the line between health and sickness. So far studies aiming at identifying risk factors have mainly come from Northern Europe and the USA. It was to understand this balance between genetics and environmental determinants better, and to tailor appropriate preventive strategies for Italian and other Southern European populations, that the Moli-sani study was launched, transforming a small Italian region into a large scientific laboratory: the "Molise lab". Each participant received a thorough medical check-up at no cost to either him/her or the national health service, resulting in thousands of hours of free public health care. With a completely computerized system, Moli-sani is a "paperless" study, in which researchers and participants communicate using recently developed technologies such as mobile phone text messages (SMS). The biological data bank (the "MoliBank") is one of the largest in Europe. Paying particular attention towards innovation and new technologies, the Moli-sani study has placed itself at the cutting edge of a new paradigm crossing research and prevention

NCT ID: NCT03240523 Recruiting - Uterine Fibroids Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Compare to Ulipristal

ASTEROID 5
Start date: July 31, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal The secondary objective of this study is to evaluate the efficacy and safety of different treatment regimens of vilaprisan in subjects with uterine fibroids

NCT ID: NCT03240250 Recruiting - Lung Cancer Clinical Trials

Randomized Study on Effects of Uniportal VATS Versus Triportal VATS

Start date: March 12, 2017
Phase: N/A
Study type: Observational

For the treatment of stage I-II NSCLC, two mini-invasive techniques are mostly utilized: uni-portal and three-portal VATS. In the uniportal approach, the injury on a single intercostal space could determine a lower level of pain than the three-portal approach, allowing a better postoperative course. Few studies in Literature compare these techniques, and most of them are retrospective. The main purpose of this randomized study is to compare uni-portal VATS with three-portal VATS, in terms of postoperative pain. Secondary objectives of the study are valutations of: - respiratory and functional capacity between the two groups - operative time - number of resected lymphnodes - intra and postoperative complications, such as conversions to open surgery, amount of bleeding, prolonged air leaks, surgical site infections, pulmonary complications.

NCT ID: NCT03240211 Not yet recruiting - CTCL Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Start date: September 10, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, multi-arm, international, phase Ib, 3 x 3 dose-escalation study with an initial phase I followed by an expansion phase. The primary objective of the phase Ib is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dose limiting toxicity (DLT) of various combinations of pembrolizumab, pralatrexate and decitabine.

NCT ID: NCT03238534 Not yet recruiting - GERD Clinical Trials

Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

Start date: October 2017
Phase: Phase 4
Study type: Interventional

Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain

NCT ID: NCT03237910 Not yet recruiting - Clinical trials for Ventricular Fibrillation

Real Time Amplitude Spectrum Area to Guide Defibrillation

AMSA
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

AMSA trial is a multicenter, randomized, controlled study in out-of-hospital cardiac arrest patients. The purpose of the study is to test the hypothesis that a real time AMSA analysis during CPR may predict the success of defibrillation and optimize the timing of defibrillation delivery. The primary end-point is the efficacy of the AMSA-CPR: termination of VF/VT with achievement of ROSC for an AMSA ≥ 15.5 mV-Hz All patients meeting inclusion/exclusion criteria and receiving cardiopulmonary resuscitation are randomized into two groups: AMSA-guided CPR or standard CPR. In the AMSA-CPR group, AMSA value suggests when the rescuer should deliver the defibrillation attempt; In the Standard-CPR group, the defibrillation is delivered based on the 2015 European Resuscitation Council (ERC) CPR guidelines.